Back to results
US 2008/0188641 A1Published application
Methods for detecting and inhibiting angiogenesis
AssigneeUniversity of California, San Diego
InventorJudith A. Varner
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of California, San Diego
InventorJudith A. Varner
Estimating the term…
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.
A method of identifying an α5β1 integrin antagonist agent, said method comprising identifying an agent as reducing or inhibiting angiogensis associated with α5β1 integrin expression ina tissue by detecting said agent as interfering with α5β1 integrin binding to its ligand.
A method od preparing an α5β1 integrin antagonist peptide, said method comprising chemically synthesizing a peptide identified as reducing or inhibiting angiogenesis associated with α5β1 integrin expression in a tissue by said peptide's interference with α5β1 integrin binding to its ligand.
A method of determining a peptide to be ab α5β1 integrin antagonist peptide, said method comprising
A method of preparing an α5β1 integrin peptide, said method comprising chemically synthesizing an α5β1 integrin antagonist peptide that inteferes with α5β1 integrin binding to its ligand and reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue.
Dependencies are inferred from the claim text.